Abstract
One hundred and ten adult patients with non-Hodgkin's lymphoma (NHL) received an autologous hematopoietic cell transplant (ABMT) from 1988 to 1993. All received a uniform preparative regimen of cyclophosphamide, BCNU and etoposide (CBV). Twenty-one percent had low grade histologies, 54% intermediate grade, and 25% high grade. Median follow-up of 48 survivors is 100 months. Kaplan–Meier 10 year overall survival and relapse-free survival for the entire group is 42% and 32%, respectively. Fifty patients were in complete remission 2 years post transplant. With additional follow-up, patients with high grade malignancies are cured, while patients with intermediate or low grade histologies were at continued risk of relapse up to 5 years post transplant. Of 39 patients in complete remission 5 years post transplant, none have relapsed with additional extended follow-up. We conclude that patients with NHL treated with ABMT, if in CR 5 years post transplant, are at very low risk of relapse with extended follow-up, suggesting the possibility of cure for all histologies, including those with low grade NHL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540 1545
Vose J, Zhang MJ, Rowlings P et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients achieving remission: a report from the Autologous Blood and Marrow Registry J Clin Oncol 2001 19: 406 413
Copelan EA, Penza SL, Pohlman B et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma Bone Marrow Transplant 2000 25: 1243 1248
Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose chemotherapy in poor risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87–2 Protocol – a groupe d'etude des lymphomes de l'adulte study J Clin Oncol 2000 18: 3025 3030
Wheeler C, Strawderman M, Ayash L et al. Prognostic factors for treatment outcome in autotransplantation of intermediate grade with high grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide J Clin Oncol 1993 11: 1085 1091
Philip T, Armitage J, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of chemotherapy in adults with intermediate grade or high grade non-Hodgkin's lymphoma New Engl J Med 1987 316: 1493 1498
Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma J Clin Oncol 1995 13: 588 595
Cervantes F, Shu XO, McGlave PB et al. Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma Bone Marrow Transplant 1995 16: 387 392
Foran JM, Apostilidis J, Papamichael D et al. High-dose therapy with autologous hematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre Ann Oncol 1998 9: 865 869
Vose J, Bierman P, Lynch J et al. Effect of follicularity on autologous transplantation for large cell non-Hodgkin's lymphoma J Clin Oncol 1998 16: 844 849
Voso MT, Martin S, Hohaus S et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT) Bone Marrow Transplant 2000 25: 957 964
Bierman P, Vose J, Anderson B . High dose chemotherapy with autologous hematopoietic rescue for follicular low grade non-Hodgkin's lymphoma J Clin Oncol 1997 15: 445 450
Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor prognosis follicular lymphoma Blood 1995 86: 3257 3262
Haas R, Moos M, Mohle R et al. High-dose therapy with peripheral blood progenitor cell transplantation in low grade non-Hodgkin's lymphoma Bone Marrow Transplant 1996 17: 149 155
Bolwell B, Goormastic M, Andresen S . Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point Bone Marrow Transplant 1997 19: 443 448
Rosenberg S, Berard C, Brown B et al. National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphoma's, Summary and Description of a Working Formulation for Clinical Usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project Cancer 1982 49: 2112 2135
Shipp MA, Harrington DP, Anderson JR et al. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma New Engl J Med 1993 329: 987 994
Weisdorf D, Andersen J, Glick J et al. Survival after relapse of low grade non-Hodgkin's lymphoma: implications for marrow transplantation J Clin Oncol 1992 10: 942 947
Bastion Y, Sebban C, Berger F et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients J Clin Oncol 1997 15: 1587 1594
Gallagher CJ, Gregory WM, Jones AE et al. Follicular lymphoma: prognostic factors for response and survival J Clin Oncol 1986 4: 1470 1480
Paryani S, Hoppe R, Cox R et al. Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II Cancer 1983 52: 2300 2307
Lawrence T, Urba W, Steinberg S et al. Retrospective analysis of stage I and stage II indolent lymphomas at the National Cancer Institute J Radiat Oncol Biol Phys 1988 14: 417 424
Vaughan Hudson B, Vaughan Hudson G, MacLennan KA et al. Clinical stage I non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy Br J Cancer 1994 69: 1088 1093
MacManus M, Hoppe R . Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University J Clin Oncol 1996 14: 1282 1290
Apostilidis J, Gupta R, Grnezelias D et al. High-dose chemotherapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up J Clin Oncol 2000 18: 527 536
Freedman A, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 1999 94: 3325 3333
Horning S, Negrin R, Hoppe R et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial Blood 2001 97: 404 409
Micaleff I, Lillington D, Apostilidis J et al. Therapy related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor cell support for lymphoid malignancies J Clin Oncol 2000 18: 947 955
Milligan D, Ruiz de Elvira M, Kolb HJ et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT Br J Haematol 1999 106: 1020 1026
Armitage J . Editorial: myelodysplasia and acute leukemia after autologous bone marrow transplantation J Clin Oncol 2000 18: 945 946
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bolwell, B., Kalaycio, M., Sobecks, R. et al. Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplant 29, 673–679 (2002). https://doi.org/10.1038/sj.bmt.1703525
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703525
Keywords
This article is cited by
-
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation
Bone Marrow Transplantation (2012)
-
Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia
Bone Marrow Transplantation (2007)